VOLGA

1. 02:15
   ESMO 2026 现场信号

   Is Less Enough and More Too Much? Implications of #VOLGA for the Peri-Operative Therapeutic Landscape in MIBC. Presented by @MichvdHeijden @NKI_nl. #ESMO26 written coverage by @cha
2. 00:42
   ESMO 2026 现场信号

   The interim analysis of the phase 3 VOLGA study found improved EFS for patients with MIBC when treated with neoadjuvant durvalumab & enfortumab vedotin.

1. 23:23
   ESMO 2026 现场信号

   *VOLGA study* cis-ineligible/refused @tompowles1 @MichvdHeijden @myESMO #ESMO26 @oncodaily @OncoAlert
2. 22:45
   ESMO 2026 现场信号

   Perioperative Durvalumab ± Tremelimumab + Neoadjuvant EV in MIBC: Phase 3 VOLGA Trial. Presented by @tompowles1 @QMBCI. #ESMO26 written coverage by @chavarriagaj @PSH_Urology >
3. 22:15
   ESMO 2026 现场信号

   #ESMO26|#VOLGA
4. 22:00
   ESMO 2026 现场信号

   Original Article: Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer (phase 3 VOLGA trial) https://nej.md/4z7dQFm
5. 20:31
   ESMO 2026 现场信号

   👥 Consenso de los KOLs en #ESMO26 ¿quién apoya cada ensayo?
6. 20:17
   ESMO 2026 现场信号

   VOLGA delivers meaningful survival benefit.
7. 20:00
   ESMO 2026 现场信号

   🚨 Positive results from the phase 3 VOLGA trial presented at #ESMO26
8. 18:31
   ESMO 2026 现场信号

   #ESMO26 VOLGA (phase III, N=695): MIBC patients ineligible for or declining cisplatin. Perioperative durvalumab + neoadjuvant enfortumab vedotin vs radical cystectomy ± adjuvant th
9. 14:37
   ESMO 2026 现场信号

   My take on VOLGA at #ESMO26:
10. 13:55
    ESMO 2026 现场信号

    The #OncoAlertTopTweet Day2 of #ESMO26
11. 12:49
    ESMO 2026 现场信号

    Five absolute signals after PS I #ESMO26
12. 11:52
    ESMO 2026 现场信号

    VOLGA試験：ctDNAクリアランスと予後
13. 08:08
    ESMO 2026 现场信号

    #ESMO26 #GU #UC #MIBC
14. 07:06
    ESMO 2026 现场信号

    Inspiring to be at the first presidential session of #ESMO26 with two P3 trials pushing the boundaries of perioperative cancer treatment in very different ways.
15. 03:09
    ESMO 2026 现场信号

    🚨⭐ #ESMO26 | GU ONCOLOGY — DAY 2 HIGHLIGHTS
16. 03:00
    ESMO 2026 现场信号

    #ESMO26 | Abstract #LBA2 | VOLGA | Presented by @tompowles1 | @OncoAlert
17. 02:15
    ESMO 2026 现场信号

    💥 Survival was improved with durvalumab plus enfortumab vedotin in patients with MIBC according to new data from the phase 3 VOLGA trial
18. 02:05
    ESMO 2026 现场信号

    Congratulations @tompowles1 and team! EVD #VOLGA #ESMO26
19. 01:58
    ESMO 2026 现场信号

    📌 An OncoAlert #Podium2Screen from the #ESMO26 Presidential Session
20. 01:57
    ESMO 2026 现场信号

    #ESMO26 Very thoughtful and balanced discussion of VOLGA trial by @MichvdHeijden , putting EV-D in perspective with EV-303/B15 on efficacy & safety.
21. 01:41
    ESMO 2026 现场信号

    🚨⭐ #ESMO26 | GU ONCOLOGY — DAY 2 HIGHLIGHTS
22. 01:26
    ESMO 2026 现场信号

    VOLGA at #ESMO2026: Perioperative durvalumab plus neoadjuvant enfortumab vedotin significantly improved EFS and OS in patients with MIBC ineligible for or refusing cisplatin. @tomp
23. 01:23
    ESMO 2026 现场信号

    A new SoC in cisplatin ineligible muscle-invasive bladder cancer: The VOLGA Trial. Neoadjuvant Durva plus EV, without adjuvant EV. Less is more. #BladderCancer #ESMO26 @myESMO @sog
24. 01:21
    ESMO 2026 现场信号

    #ScienceLink #Madrid2026 #ESMO26 #VOLGA #Durvalumab
25. 00:59
    ESMO 2026 现场信号

    🚨⭐🟠 #ESMO26 | Presidential Symposium | LBA2 | VOLGA
26. 00:55
    ESMO 2026 现场信号

    Kudos @tompowles1 on a fantastic #VOLGA presidential @ #ESMO26 👏
27. 00:42
    ESMO 2026 现场信号

    🎯 #ESMO2026 | VOLGA: pueden cambiar la práctica clínica en cáncer de vejiga músculo-invasivo.
28. 00:17
    ESMO 2026 现场信号

    Day 2 (Presidential) #ESMO26
29. 00:12
    ESMO 2026 现场信号

    VOLGA tested for the 1st time a triplet with ADC + dual checkpoint inhibition in the neoadjuvant setting for cis-ineligible MIBC #ESMO26
30. 00:09
    ESMO 2026 现场信号

    As presented at #ESMO2026, perioperative #durvalumab plus neoadjuvant enfortumab vedotin significantly improved survival in patients with muscle-invasive bladder cancer who were in
31. 00:01
    ESMO 2026 现场信号

    Important data by Dr. Bedke & @AndreaNecchi in localized MIBC: periop addition of anti-PD1 not better vs neoadjuvant Gem/Cis alone; discordant with NIAGARA data. Periop EV/ICI
32. 00:01
    ESMO 2026 现场信号

    #ESMO26: i risultati dello studio VOLGA aprono nuove prospettive nella cura del #tumoredellavescica muscolo-invasivo.

1. 23:59
   ESMO 2026 现场信号

   Resultados de VOLGA presentados en #ESMO26 @tompowles1
2. 23:47
   ESMO 2026 现场信号

   #ESMO26 Dr. Michiel van der Heijden discussed the implications of VOLGA alongside KEYNOTE-905 and KEYNOTE-B15:
3. 23:46
   ESMO 2026 现场信号

   Fantastic presentation by @tompowles1 @Uromigos on VOLGA trial showing practice changing EFS/OS benefit with neoadjuvant EV/durva ->RC ->durva vs no peri-op Tx in cisplatin-u
4. 23:43
   ESMO 2026 现场信号

   #ESMO26 VOLGA: Could just 3 cycles of neoadjuvant EV redefine treatment for cisplatin-ineligible MIBC?
5. 23:42
   ESMO 2026 现场信号

   👑 This is why #Podium2Screen works!
6. 23:37
   ESMO 2026 现场信号

   #ESMO26 | VOLGA in cisplatin-ineligible MIBC: Durvalumab + enfortumab vedotin significantly improved: OS: HR 0.58 (p=0.0027) EFS: HR 0.51 (p<0.0001) 2-year OS: 78% vs 69%ctDNA c
7. 23:33
   ESMO 2026 现场信号

   Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: Results From the Phase 3 VOLGA Trial
8. 23:32
   ESMO 2026 现场信号

   VOLGA trial : The Arm1 - in MIBC, neoadjuvant Durvalumab + EV followed by surgery then adjuvant Durvalumab showed better EFS (NR vs 12 months HR 0.51) and OS (NR in both arms, HR 0
9. 23:31
   ESMO 2026 现场信号

   🔊👏Bravo Dr Thomas Powles @TomPowles1 Outstanding Presentation @ Presidential Symposium, Topline Results VOLGA Trial, Perioperative durvalumab w/ or without tremelimumab + neoadj en
10. 23:30
    ESMO 2026 现场信号

    VOLGA also explored short periods of EV with duvalumab and tremelimumab in muscle invasive bladder cancer #ESMO26 @NEJM. Results showed EVDT improved EFS vs cystectomy (HR 0.61).
11. 23:29
    ESMO 2026 现场信号

    @tompowles1 presented VOLGA at #ESMO26: perioperative durvalumab + neoadjuvant EV vs control in cisplatin-ineligible MIBC
12. 23:29
    ESMO 2026 现场信号

    An OncoAlert #Podium2Screen from the #ESMO26 Presidential Session
13. 23:26
    ESMO 2026 现场信号

    An important practical question from VOLGA:
14. 23:26
    ESMO 2026 现场信号

    Volga EFS and OS for Durva/EV and Durva/Treme #ESMO26 #oncoalert
15. 23:26
    ESMO 2026 现场信号

    @tompowles1 with #VOLGA phase 3 of EV-durva, EV-tremi-durva, vs cystectomy. EV-durva improved EFS & OS. Great to see survival improved w neoadj doublet. Triplet misses partly d
16. 23:26
    ESMO 2026 现场信号

    A fascinating VOLGA finding:
17. 23:25
    ESMO 2026 现场信号

    Strong VOLGA Phase III results at #ESMO26!
18. 23:24
    ESMO 2026 现场信号

    #ESMO26 🔬 VOLGA (Phase 3)
Peri-op durvalumab ± tremelimumab + neoadjuvant EV ×3 vs upfront cystectomy in cisplatin-ineligible MIBC
19. 23:24
    ESMO 2026 现场信号

    #ESMO26 @tompowles1 presents at the 👑presidential 👑 session VOLGA n=1009 phIII neoadjuvant #bladdercancer trial. 24mo EFS 63.5% vs 45% (HR 0.51), pCR 45% vs 10%. Triplet +tremelimu
20. 23:23
    ESMO 2026 现场信号

    Looking for context to interpret VOLGA at #ESMO26 after the presentation in the presidential session?
21. 23:22
    ESMO 2026 现场信号

    These are THE curves. Volga . New SOC .@tompowles1 @myESMO #ESMO26 @OncoAlert @OncBrothers . 3 dose of Pre operative EV are enough.
22. 23:21
    ESMO 2026 现场信号

    VOLGA explored short periods of EV (3 cycles) with duvalumab in muscle invasive bladder cancer #ESMO26 @NEJM. Results showed EVD was associated with better EFS + OS vs cystectomy a
23. 23:20
    ESMO 2026 现场信号

    🇬🇧 Brilliant to see @tompowles1 AGAIN on the podium, leading the way in bladder cancer!
24. 23:20
    ESMO 2026 现场信号

    🔥 Presidential Symposium I #ESMO26
25. 23:19
    ESMO 2026 现场信号

    VOLGA: perioperative EV + Durvalumab increases pCR, EFS and OS compared with cystectomy alone. A new standard option for these patients, in a setting that is becoming really crowde
26. 23:19
    ESMO 2026 现场信号

    VOLGA shows Improved EFS and OS for Durva/EV presented by @tompowles1 #ESMO26 #oncoalert
27. 23:18
    ESMO 2026 现场信号

    Excellent presentation by @tompowles1! VOLGA: perioperative durvalumab + 3 cycles of neoadjuvant EV improved EFS (HR 0.51) and OS (HR 0.58) vs cystectomy ± adjuvant therapy in cisp
28. 23:17
    ESMO 2026 现场信号

    #ESMO26 | VOLGA
29. 23:16
    ESMO 2026 现场信号

    Presidential symposium 1️⃣!!
30. 23:15
    ESMO 2026 现场信号

    VOLGA: OS benefit without adjuvant EV.
31. 23:00
    ESMO 2026 现场信号

    #ESMO26: Neoadjuvant enfortumab vedotin significantly improved event-free and overall survival when added to peri-operative durvalumab for muscle-invasive #BladderCancer (#MIBC) in
32. 22:41
    ESMO 2026 现场信号

    #ESMO26 NEJM
33. 22:36
    ESMO 2026 现场信号

    The #ESMO26 Presidential Symposium is about to begin! 🔥
34. 22:35
    ESMO 2026 现场信号

    Presented at #ESMO26:
35. 22:27
    ESMO 2026 现场信号

    🔥 full house before #ESMO26 Presidential:
36. 20:53
    ESMO 2026 现场信号

    🔥 #ESMO2026 late-breakers 24 Oct scored 1–10 for SoC impact
37. 20:45
    ESMO 2026 现场信号

    OncoAlert 4Sight Abstracts to be Presented at #ESMO26
38. 19:10
    ESMO 2026 现场信号

    🚨 #IUCS Clinical Poll | #ESMO26
39. 14:50
    ESMO 2026 现场信号

    With VOLGA results coming at #ESMO26, a summary of contemporary phase III perioperative trials in muscle-invasive bladder cancer.
40. 14:09
    ESMO 2026 现场信号

    VOLGA (LBA2, #ESMO26): cisplatin-ineligible/refusing MIBC — neoadjuvant enfortumab vedotin + peri-op durvalumab vs control.
41. 13:45
    ESMO 2026 现场信号

    An important survival result in muscle-invasive bladder cancer from #ESMO26 📊
42. 11:26
    ESMO 2026 现场信号

    IO + EV upfront is now the SoC for MIBC!! But how much EV do we need in postOP settings? Eagerly looking forward to more data/discussion on Day 2 #ESMO26! VOLGA as the new SoC!!??!
43. 10:30
    NEJM

    VOLGA试验：度伐利尤单抗联合特雷梅利尤单抗和恩福妥单抗维替妥治疗肌层浸润性膀胱癌

    NEJM Ahead of Print 发表 VOLGA 试验结果，评估度伐利尤单抗、特雷梅利尤单抗联合恩福妥单抗维替妥治疗肌层浸润性膀胱癌的疗效。DOI: 10.1056/NEJMoa2608323

44. 06:52
    ESMO 2026 现场信号

    #ESMO26 | VOLGA | Presidential Symposium-1

1. 20:06
   ESMO 2026 现场信号

   Excellent presentation by Jens presenting results from KN866 trial that did not meet its primary endpoint in contrast with NIAGARA. Peri-op EV-pembro is the SOC in MIBC, awaiting V
2. 19:46
   ESMO 2026 现场信号

   Full house for Bladder/RCC updates first with #KN866 #ESMO26
3. 17:25
   ESMO 2026 现场信号

   🚨 #ESMO26 GU Oncology — the studies I would keep closest on the radar
4. 16:37
   ESMO 2026 现场信号

   Lovely walking tour & sunset in Madrid @myESMO #ESMO26
5. 07:19
   ESMO 2026 现场信号

   ✈️ En route to Madrid for #ESMO26, landing just in time for the data to start Friday morning. Most excited for: VOLGA LBA2 in bladder cancer, INTerpath-001's first phase 3 neoantig
6. 04:15
   ESMO 2026 现场信号

   🔬 GU cancer data to watch at #ESMO26:

1. 03:05
   ESMO 2026 现场信号

   The ten trials oncologists are waiting for at #ESMO26, ranked by how many physicians posted about each one before Madrid. Top three: VOLGA, INTerpath-001, DeLLphi-305. Flagged by @…

1. 17:30
   ESMO 2026 现场信号

   🚨 #ESMO26 GU Oncology — Top picks by OncoAlert 🎯 #BladderCancer : VOLGA, KEYNOTE-B15, ENERGIZE, KEYNOTE-866 #ProstateCancer: DASL-HiCaP, CAPItello-281, PROTEUS #KidneyCancer: LITE…

1. 22:15
   ESMO 2026 现场信号

   2/4 #BladderCancer at #ESMO26 🟢 #VOLGA — LBA2 - Positive EFS/OS topline announced for durva + EV. Looking for the magnitude of benefit, surgical outcomes, and toxicity. - We know …
2. 08:02
   ESMO 2026 现场信号

   #ESMO26 is nearly here, and I'm hyped. Ten of 12 Presidential abstracts are expected to show primary endpoints met. Seven have declared a survival win, including the VOLGA trial no…

当前热度 305·可比范围峰值 383（10月25日 04:00）·近 24 小时可比范围变化 -20%·当前参与者 60

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。